chronic lymphocytic leukemia

Clinical Images
Electro-Anatomically-Guided Endomyocardial Biopsy in a Patient With Focal Myocardial Infiltration and Chronic Lymphocytic Leukemia
02/15/2024
A 53-year-old female was admitted to the cardiology department on account of signs and symptoms of congestive heart failure with severe peripheral edema and dyspnea on exertion (New York Heart Association class III) for the past 3 months.
A 53-year-old female was admitted to the cardiology department on account of signs and symptoms of congestive heart failure with severe peripheral edema and dyspnea on exertion (New York Heart Association class III) for the past 3 months.
A 53-year-old female was...
02/15/2024
Journal of Invasive Cardiology
Research Reports
The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences
06/21/2022
Dr Davids and colleagues estimated the total cumulative costs per patient of treatment sequences for adults with chronic lymphocytic leukemia, with and without deletion 17p, as well as the budget impact of introducing sequences with...
Dr Davids and colleagues estimated the total cumulative costs per patient of treatment sequences for adults with chronic lymphocytic leukemia, with and without deletion 17p, as well as the budget impact of introducing sequences with...
Dr Davids and colleagues...
06/21/2022
Journal of Clinical Pathways
News
Acalabrutinib Improves PFS and OS Over Other First-Line Regimens in CLL
02/16/2021
02/16/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL
12/09/2020
12/09/2020
Journal of Clinical Pathways
Conference Coverage
Ibrutinib Dose Reductions and Discontinuations for CLL in Routine Practice vs Clinical Trials
12/04/2020
12/04/2020
Journal of Clinical Pathways
Novel Ibrutinib Combination for Primary Treatment of CLL
Interview
Novel Ibrutinib Combination for Primary Treatment of CLL
06/22/2020
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On...
06/22/2020
Journal of Clinical Pathways
Understanding New Treatments for Chronic Lymphocytic Leukemia
04/04/2016
JCP Editors
Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...
Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...
Recent...
04/04/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use